Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (11766)	2/16/2013 9:15:49 AM
From: Bradpalm1	5 Recommendations Respond to of 13111

Of course he knows this. This is another Straw Man Argument against the efficacy of PV-10. Consider the source.

To: Mimbari who wrote (11766)	2/16/2013 10:00:18 AM
From: NTTG	1 Recommendation Read Replies (1) \| Respond to of 13111

Correct, the company assumption is that vaccination as a result of PV-10 treatment sensitizes the immune system to all systemic tumors of similar type, so the subsequent detection of metastatic disease of the lung should not happen. Based directly on the argument the company makes from 5 mice as their current MOA proof of concept. Your concern about dose and timing simply shines a bright light on the lack of available data on appropriate PV-10 use. On the cusp of a PIII trial the company has no dose ranging, time interval, or 'booster effect' insight to guise dosing discussion, or the timing of appropriate end points. Case 2 directly challenges the assumptions made by PVCT, you will see more of this as additional cases are reported.